

February 2, 2010

Seeking children with Tourette syndrome ages 8 to 17 years

Dear Colleagues:

Recognizing the limitations of currently available tic suppressing medications, Dr's Singer and Grados at Johns Hopkins are investigating the safety, tolerability, and efficacy of glutamate modulating agents for tic suppression: a glutamate antagonist (riluzole) and a glutamate agonist (D-serine).

This is an NIH funded, 8-week total (6-week treatment, 2-week taper) randomized, three-arm, parallel group, double-blind, flexible dose, placebo-controlled treatment study.

We would greatly appreciate your assistance in recruiting subjects for this JHH IRB approved study.

Criteria:


- Diagnosis of Tourette syndrome
- Ages: 8-17 years, male or female
- Total Tic Score of ≥ 22 on the YGTSS
- ADHD, OCD are not exclusions
- Can be on other tic-suppressing medications, if agrees to maintain a stable dosage
- No other major medical or psychiatric problems
- Weight ≥ 33 kg

There is no cost to the subject/family. All patients will be required to have a screening evaluation by Dr. Singer at Johns Hopkins.


For more information or referral of subjects, please contact Sr. Research Assistant, Christina Morris at 410-955-1960, Christina.morris@jhmi.edu.

We thank you for your assistance.

Sincerely,



Harvey S. Singer, M.D.
Pediatric Neurology
200 N Wolfe St
Suite 2158
Baltimore, MD 21287
(410) 955-7212



Marco Grados, M.D.
Psychiatry and Behavioral Sciences
600 N Wolfe St
CMSC 340
Baltimore, MD 21287
(443) 287-2291